SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) June 20, 1996
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification no.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On June 20, 1996 Biocontrol Technology, Inc.
(NASDAQ:BICO) announced that ongoing patient testing of
its production model Diasensor 1000 noninvasive
glucose sensor for diabetics continues to show
significantly improved performance.
A total of seven patients are currently in the
testing process which will ultimately result in 60-day
evaluation periods for each. To date, three of the
seven patients have been through the full 60-day
period. The Diasensor 1000 production model provided
consistent, accurate readings on 66% of the tested
patients and gave readings 85% of the time.
Significantly improved also was the accuracy of
the glucose measurement readings on the Diasensor 1000
production model, which was 15% of the actual glucose
readings using the Yellow Springs Instrument laboratory
reference device for comparison.
The production model Diasensor 1000 has also
demonstrated increased speed of data collection. What
took six hours to collect with the BETA device now
takes just 15 minutes.
The testing process will continue through each of
the seven patients after which the data will be
submitted to the FDA as part of BICO's revised 510(k)
submission.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits-Press Release
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: June 20, 1996
